HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

Market Cap	814.33B
Revenue (ttm)	55.30B
Net Income (ttm)	-28.85B
Shares Out	83.78M
EPS (ttm)	-376.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350,562
Average Volume	540,738
Open	9,860.00
Previous Close	9,850.00
Day's Range	9,710.00 - 10,080.00
52-Week Range	4,780.95 - 16,857.00
Beta	-0.07
RSI	33.97
Earnings Date	Feb 21, 2025

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 93
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115450

Financial Performance

In 2023, HLB Therapeutics's revenue was 53.75 billion, an increase of 26.76% compared to the previous year's 42.40 billion. Losses were -2.30 billion, -79.72% less than in 2022.